Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-IGSF11 antibody refers non-specifically to antibodies directed against **immunoglobulin superfamily member 11**. In the therapeutic context provided, the clearest identified example is **SG7**, a preclinical monoclonal antibody that blocks the **IGSF11-VISTA** immune-checkpoint interaction and is being explored as a cancer immunotherapy for solid tumors. Available information indicates antitumor activity in mouse melanoma and colon carcinoma models, including enhanced activity in combination with anti-PD-1 therapy, but no clearly established commercial brand name, manufacturer, or confirmed clinical-stage development program was identified.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-IGSF11 antibody.